DC
INO icon

Defender Capital’s Inovio Pharmaceuticals INO Stock Holding History

Defender Capital’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,587
Closed -$370K – 38
2022
Q1 		$370K Hold
8,587
– – 0.13% 27
2021
Q4 		$514K Sell
8,587
-1,869
-18% -$150K 0.16% 28
2021
Q3 		$887K Sell
10,456
-833
-7% -$83.6K 0.29% 21
2021
Q2 		$1.25M Buy
11,289
+417
+4% +$40.1K 0.42% 18
2021
Q1 		$1.21M Buy
10,872
+2,581
+31% +$339K 0.43% 20
2020
Q4 		$881K Sell
8,291
-1,702
-17% -$227K 0.38% 19
2020
Q3 		$1.39M Buy
9,993
+6,639
+198% +$1.38M 0.69% 14
2020
Q2 		$1.08M Sell
3,354
-15,668
-82% -$2.52M 0.64% 14
2020
Q1 		$1.7M Sell
19,022
-28,545
-60% -$1.76M 1.24% 13
2019
Q4 		$1.88M Sell
47,567
-4,291
-8% -$129K 1.67% 12
2019
Q3 		$1.28M Sell
51,858
-2,209
-4% -$67.2K 1.13% 11
2019
Q2 		$1.92M Sell
54,067
-3,633
-6% -$144K 1.55% 10
2019
Q1 		$2.55M Buy
57,700
+9,275
+19% +$467K 2.04% 10
2018
Q4 		$2.32M Buy
+48,425
New +$2.94M 2.21% 10

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Defender Capital's INO Position: Q2 2022 in Review

Defender Capital sold out of Inovio Pharmaceuticals (INO) in Q2 2022, closing a stake of 8,587 shares — an estimated $370K sold.

Defender Capital first reported a position in INO in Q4 2018 and held it in 14 quarters. The position peaked at $2.55M in Q1 2019. 184 funds tracked by Wall St. Rank hold INO as of Q2 2022.

  • Defender Capital reported no remaining Inovio Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Defender Capital sold 8,587 Inovio Pharmaceuticals shares in Q2 2022, an estimated $370K.
  • Defender Capital first reported a position in Inovio Pharmaceuticals in Q4 2018 and held it in 14 quarters.
  • Defender Capital's Inovio Pharmaceuticals position peaked at $2.55M in Q1 2019.
  • 184 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2022.

Based on Defender Capital's 13F filing for Q2 2022, filed 26 Jul 2022.